Coinfection between Pulmonary Tuberculosis and Systemic Lupus Erythematosus: A 20-year Bibliometric Study
John Barja-Ore1, Alexandra Liñan-Bermudez2, Brandon E Guillen-Calle3
1Academic Department, Universidad Privada Del Norte, Lima, Peru.
International Journal of Mycobacteriology
|December 18, 2025
Summary
Scientific output on pulmonary tuberculosis (PTB) and systemic lupus erythematosus (SLE) coinfection is growing. International collaboration significantly boosts citation impact, with India, China, and Brazil leading research.
Area of Science:
- Rheumatology
- Infectious Diseases
- Bibliometrics
Background:
- Pulmonary tuberculosis (PTB) is a significant complication in systemic lupus erythematosus (SLE) patients globally.
- Understanding the research landscape of PTB and SLE coinfection is crucial.
Purpose of the Study:
- To conduct a bibliometric analysis of scientific literature on PTB and SLE coinfection.
- To identify key trends, influential publications, and collaborative patterns.
Main Methods:
- Bibliometric study using Scopus database and MeSH terms.
- Analysis of 122 selected articles using SciVal, VOSviewer, and Bibliometrix tools.
Main Results:
- Annual scientific growth rate of 4.56% with 22.4 citations per publication.
- Rheumatology International (Q2) was the leading journal; India led in publications.
- International authorship correlated with higher citation impact (209.8 citations/publication).
Conclusions:
- Consistent increase in PTB and SLE research over 20 years.
- India, China, and Brazil are leading countries in this research area.
- International collaboration is increasingly important and impactful.
More Related Videos
23:06The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
Published on: August 11, 2008
19.6K
09:02An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei
Published on: February 17, 2014
20.2K
Related Concept Videos
01:28Pulmonary Tuberculosis II
1.3K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.3K
01:29Pulmonary Tuberculosis I
802
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
802
01:31Pulmonary Tuberculosis III
890
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
890
01:28Pulmonary Tuberculosis V
523
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
523
01:26Pulmonary Tuberculosis IV
468
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
468
01:22Chronic Obstructive Pulmonary Disease
2.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.2K